Approval · Notice of Compliance 21255 · 2018
PRISTIQ: Notice of Compliance 21255
Issued August 29, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21255
- Date
- August 29, 2018
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Added safety information regarding use while breastfeeding and during pregnancy in the warnings and precautions section
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PRISTIQ | Not yet assigned | — |
Medicinal ingredients
- DESVENLAFAXINE SUCCINATE 50 MG per TAB
- DESVENLAFAXINE SUCCINATE 100 MG per TAB